Background: Lymphangioleiomyomatosis (LAM) is characterised by progressive airway obstruction and hypoxaemia in young women. Although sleep may trigger hypoxaemia in patients with airway obstruction, it has not been previously investigated in patients with LAM. Methods: Consecutive women with lung biopsy proven LAM and absence of hypoxaemia while awake were evaluated with pulmonary function test, echocardiography, 6-min walk test, overnight full polysomnography, and Short Form 36 health-related quality-of-life questionnaire. Results: Twenty-five patients with (mean AE SD) age 45 AE 10 years, SpO 2 awake 95% AE 2, forced expiratory volume in the first second (medianeinterquartile) FEV 1 (% predicted) 77 (47e90) and carbonic monoxide diffusion capacity, DL CO (%) 55 (34e74) were evaluated. Six-minute walk test distance and minimum SpO 2 (medianeinterquartile) were, respectively, 447 m (411 e503) and 90% (82e94). Medianeinterquartile apnoeaehypopnoea index was in the normal range 2 (1e5). Fourteen patients (56%) had nocturnal hypoxaemia (10% total sleep time with SpO 2 <90%), and the median sleep time spent with SpO 2 <90% was 136 (13e201) min. Sleep time spent with SpO 2 <90% correlated with the residual volume/total lung capacity ratio (r s Z 0.5, p: 0.02), DL CO (r s Z À0.7, p: 0.001), FEV 1 (r s Z À0.6, p: 0.002). Multivariate linear regression model showed that RV/TLC ratio was the most important functional variable related to sleep hypoxaemia. Conclusion: Significant hypoxaemia during sleep is common in LAM patients with normal SpO 2 while awake, especially among those with some degree of hyperinflation in lung function tests. ª
Summary
Background: Lymphangioleiomyomatosis (LAM) is characterised by progressive airway obstruction and hypoxaemia in young women. Although sleep may trigger hypoxaemia in patients with airway obstruction, it has not been previously investigated in patients with LAM. Methods: Consecutive women with lung biopsy proven LAM and absence of hypoxaemia while awake were evaluated with pulmonary function test, echocardiography, 6-min walk test, overnight full polysomnography, and Short Form 36 health-related quality-of-life questionnaire. Results: Twenty-five patients with (mean AE SD) age 45 AE 10 years, SpO 2 awake 95% AE 2, forced expiratory volume in the first second (medianeinterquartile) FEV 1 (% predicted) 77 (47e90) and carbonic monoxide diffusion capacity, DL CO (%) 55 (34e74) were evaluated. Six-minute walk test distance and minimum SpO 2 (medianeinterquartile) were, respectively, 447 m (411 e503) and 90% (82e94). Medianeinterquartile apnoeaehypopnoea index was in the normal range 2 (1e5). Fourteen patients (56%) had nocturnal hypoxaemia (10% total sleep time with SpO 2 <90%), and the median sleep time spent with SpO 2 <90% was 136 (13e201) min. Sleep time spent with SpO 2 <90% correlated with the residual volume/total lung capacity ratio (r s Z 0.5, p: 0.02), DL CO (r s Z À0.7, p: 0.001), FEV 1 (r s Z À0.6, p: 0.002). Multivariate linear regression model showed that RV/TLC ratio was the most important functional variable related to sleep hypoxaemia. Conclusion: Significant hypoxaemia during sleep is common in LAM patients with normal SpO 2 while awake, especially among those with some degree of hyperinflation in lung function tests. ª 2011 Published by Elsevier Ltd.
Introduction
Lymphangioleiomyomatosis (LAM) is a rare and fatal interstitial lung disease, with an over world incidence ranging from 1 to 2.5 cases in 1 million. Although the aetiology is not completely understood, LAM is associated with tuberous sclerosis complex (TSC) 2 gene loss of heterozygosis and consequently loss in the balance between hamartin/tuberin, proteins synthesised by TSC-1/TSC-2 and extremely important in the regulation of cellular proliferation and apoptosis. LAM occurs almost exclusively in women of childbearing age, sometimes with mild symptoms as dry cough and wheezing which may lead to incorrect diagnosis of asthma or COPD in no smoking women. The most typical clinical findings, however, are dyspnoea and recurrent spontaneous pneumothorax.
1e5 LAM is characterised by progressive airway obstruction, and forced expiratory volume in 1 s (FEV 1 ) is the main variable used to determine disease severity and treatment follow-up. 6 Reduced carbon monoxide diffusion capacity (DL CO ), decreased maximal oxygen consumption (VO 2max ), and progressive worsening of hypoxaemia are common throughout the disease evolution. Although there are no established medical treatments, reports of anti-hormonal (GnRH analogue), rapamycin and doxycycline use are present in the medical literature. Hypoxaemia during exercise represents one of the first functional impairments in patients with LAM. 3 In addition to physical exercise, 11, 12 sleep may also trigger hypoxaemia. For instance, patients with chronic obstructive pulmonary disease (COPD) 9, 10 with similar pulmonary functional impairments (i.e., hyperinflation and reduced DL CO ) may experience hypoxaemia during sleep. 13 Nocturnal hypoxaemia may be associated with sleep efficiency decline, quality-of-life impairments, and development of pulmonary hypertension.
13e15 Nonetheless, to the best of our knowledge, sleep has not been previously investigated in patients with LAM.
The aim of this study was to evaluate sleep and nocturnal desaturation in patients with LAM and its relation to functional capacity, exercise, and quality-of-life variables in an outpatient population with LAM. We also evaluated nocturnal desaturation and its relation to pulmonary hypertension.
Methods

Study population
Consecutive women with LAM attending the Pulmonary Division of the Hospital das Clinicas, University of São Paulo, Brazil, were prospectively screened from January 2005 to May 2008. Eligible subjects had (1) a diagnosis of LAM confirmed by surgical lung biopsy reviewed by pathologists with pulmonary expertise from the Department of Pathology of the University of São Paulo Medical School and (2) clinical stability for at least 4 weeks, defined by the absence of hospitalisation, antibiotic use, or increase in dyspnoea. Patients using oxygen due to resting hypoxia (arterial oxygen saturation <90%), presence of chylothorax, or pneumothorax were excluded. Medications and general treatment were not modified during the protocol evaluation that was performed within an interval no longer than 8 weeks. Patients who failed to perform all functional evaluations were further excluded. Written informed consent was obtained from all subjects, and the Institutional Review Board (www.saude.gov.br/sisnep) approved the study "Estudo da função pulmonar, sono, exercício e qualidade de vida de pacientes com linfangioleiomiomatose pulmonary" number: 2645.0.015.000-05.
Pulmonary function test (PFT)
Lung volumes, flow rates, and DL CO were measured using a computerised system e Collins Plus Pulmonary Function Testing Systems (Warren E. Collins, Inc., Braintree, MA, USA) according to international guidelines recommendations. 16, 17 Post-bronchodilator volumes were registered. Percentages of predicted values were derived from standard equations. 18, 19 All tests were done in the same respiratory physiology laboratory under a barometric pressure around 695 mm Hg. Baseline dyspnoea index was used to evaluate resting dyspnoea. 20 
Six-minute walk test (6MWT)
Six-minute walk tests (6MWT) were conducted in a 50-m long flat straight corridor in the outpatient clinic of Hospital das Clinicas by a respiratory therapist trained in basic life support. Every patient performed the test according to the ATS recommendations. 21 No supplemental oxygen was used. Distance in metres, continuous oxygen saturation level, DSpO 2 (D: initial SpO 2 À final SpO 2) , and Borg index (limbs and dyspnoea) were registered. Predicted distances were calculated according to reference equations for healthy adults. 22 
Polysomnography
All participants underwent a standard overnight polysomnography (EMBLA; Flaga hf. Medical Devices, Reykjavik, Iceland), including electroencephalography, electrooculography, electromyography, oximetry, nasal thermistor, a cannula for airflow and ribcage and abdominal belts to detect breathing movements as previously described. 23 Apnoea was defined as complete cessation of airflow for at least 10 s. Hypopnoea was defined as a decrease to less than 70% of baseline on either inductance plethysmography channel or nasal cannula airflow, for 10 s or longer and associated with 4% desaturation or more. The apnoeaehypopnoea index (AHI) was calculated as the total number of respiratory events (apnoeas plus hypopnoeas) per hour of sleep. The AHI cut-off for no obstructive sleep apnoea (OSA), mild to moderate OSA, and severe OSA was, respectively, less than 5, 5e15, and more than 15 events per hour of sleep. Other measures included the magnitude of nocturnal oxygen desaturations, expressed by minimum nocturnal SpO 2 and total time with SpO 2 less than 90% (time SpO2 <90%). Clinically relevant nocturnal desaturation was defined as a fall in SpO 2 below 90% for at least 10% of total sleep time.
Echocardiography
Echocardiographic images were obtained in the parasternal long-axis and short-axis, the apical long-axis, and the apical 4-chamber view, according to current standards, by personnel blinded to the results of the polysomnography and PFT. Left atrial diameter (LAD), left ventricle (LV) end-diastolic internal dimension (LVEDD), LV end-systolic internal dimension, interventricular septal thickness (IVST), and LV posterior wall thickness (LVPWT) were determined from M-mode measurements. In addition, we obtained the LV ejection fraction and LV mass measurements. Echocardiography was performed according to the Brazilian Society of Cardiology Guidelines. 25 Ejection fraction lower than 65% and systolic arterial pulmonary pressure higher than 40 mm Hg were considered abnormal.
Questionnaires
Each subject completed the Short Form 36 (SF-36) 26, 27 questionnaire measuring generic health-related quality of life (HRQL); the baseline dyspnoea and Borg index (BDI) measuring basal and exercise shortness of breath, respectively, 20, 28 Epworth Sleepiness Score 29 and Berlin 30 measuring excessive daytime somnolence and risk to OSA, respectively.
Analysis
Continuous variables are presented as mean (SD) or median/ interquartile range (IQR), and categorical variables are presented as frequency (percentage) except where stated. To investigate the possible association between oxygen desaturation during sleep and functional variables determined while awake, Spearman correlation coefficients were calculated between time SpO 2 <90% on PSG with functional parameters while awake, including PFT and 6MWT variables. Differences across groups were compared using the Wilcoxon Rank Sum test where distribution was skewed. Stepwise multiple logistic regressions were used to select the significant predictors for oxygen desaturation. Model assumptions were assessed by residual plots. Data were analysed with statistical software (SPSS 14.0; SPSS; Chicago IL). All p values are two-tailed, and values <0.05 are considered statistically significant.
Results
Demographic and functional characteristics of the population
Thirty women were initially evaluated. Five were excluded because they did not fulfil biopsy review criteria (n Z 2), were using continuous oxygen therapy due to awake hypoxaemia (n Z 1), and failed to perform all tests (n Z 2). Therefore, a total of 25 patients completed the protocol (Fig. 1) . The time lag between LAM diagnosis and study evaluation was 2 AE 0.8 years. The demographic and functional variables, including pulmonary function test and 6MWT of the population studied are presented in Table 1 . At the time of the study, all but three patients were being treated with anti-hormonal therapy (GnRH analogue), which lead to a state of chemical menopause. Patients did not have hypoxaemia while awake (Table 1) , due to the study design, and the baseline dyspnoea index was in the normal range [median: 25e75%, interquartile: 3 (2e4)]. As expected, pulmonary function tests revealed an obstructive pattern with reductions in predicted FEV 1 and DL CO . At the end of the 6MWT, median/IQR Borg dyspnoea was 3 (2e4.5), and 11 patients had developed SpO 2 <90% (mean AE SD e minimal 6MWT SpO 2 77 AE 7%). 
Polysomnography
Polysomnography findings are summarised in Table 2 . Generally, sleep efficiency, median apnoeaehypopnoea index (AHI), and AHI in REM were in the normal range. Four patients had an AHI >5 events/h (mean AE SD e AHI 10.2 AE 4.9). Despite the absence of hypoxaemia while awake and the absence of significant sleep apnoea disorder, patients frequently had oxygen desaturation (Table 2) . While ventilation and oxygen saturation remained stable during most of the slow wave sleep phase (S3eS4), desaturation was much more common during REM sleep, with irregular ventilatory pattern, especially during clusters of eye movements. Figs. 1e5 represent the most common polysomnography pattern observed among this set of patients with LAM. Based on oxygen saturation, patients were stratified into nondesaturators and desaturators during sleep (Table 3 ). Nondesaturators and desaturators were similar regarding age and BMI and had a slightly lower SpO 2 while awake with no statistical significance. In contrast, desaturators had significantly lower FEV 1 , DL CO , final SpO 2 in 6MWT, and a higher RV/TLC ratio.
Echocardiography
Twenty-one patients of the total of 25 performed thoracic echocardiography. The 4 patients who were not able to undergo echocardiography, due to transportation limitations, had pulmonary function similar to the median values of the whole population (data not shown). Left ventricular ejection fraction was 70 AE 6%, and no pulmonary hypertension or LV systolic dysfunction was found in our population (Table 4) .
Nocturnal hypoxaemia and relation to functional variables Tables 3 and 4 . Multivariate linear regression model yielded that among these functional covariates RV/TLC was the remaining variable statistically related to nocturnal sleep hypoxaemia in the model (Table 5 ).
Questionnaires
Two SF-36 domains (physical and emotional roles) were the most impaired domains in the whole population. Both had statistically significant differences and were worse in sleep desaturators than in nondesaturators ( Table 6 ). The Epworth Sleepiness Scale (ESS) results yielded that 2 women in both groups presented a score higher than (8:1) nondesaturators (age 35 and 40), EES (13, 17) , apnoea index (5.1 and 4.0); desaturators (age 31 and 36), EES (9,10), apnoea index (6.0 and 5.5) [no significant statistical difference was observed p Z 0.74]. Berlin questionnaire did not yield differences among both groups too.
Discussion
This is the first study that systematically evaluated sleep in patients with LAM. Our study conveys several novel findings. First, 56% of the patients had significant nocturnal hypoxaemia during sleep despite normal oxygen saturation while awaken. Second, despite the menopause induced by GnRH analogue treatment, obstructive sleep apnoea was not common among patients with LAM. Third, nocturnal hypoxaemia did not correlate with demographic characteristics or awaken SpO 2 .
Lastly, nocturnal hypoxaemia correlated with pulmonary function variables, including FEV 1 , RV/TLC, DL CO , and minimum SpO 2 on 6MWT. Multivariate analysis showed that nocturnal hypoxaemia correlation to RV/TLC ratio was the most important one.
These findings indicate that nocturnal desaturation is a much more common problem in clinical practice than would have been supposed by current outpatient management based only on resting PFT and oximetry. The strength of it is that we consecutively screened an entire LAM outpatient clinic population with resting, exercise, and nocturnal oximetry. The majority of patients were not in an advanced disease stage, and we looked for possible earlier predictor variables of functional deterioration. Patients had mild obstructive ventilatory disturbance and moderate impairment in DL CO , and none of them had severe obstructive sleep apnoea (OSA). Because the GnRH analogue induced menopause could be responsible for increasing sleep apnoea, OSA was a concern for us during the design of study. 31 This finding ensured us about the safety of anti-hormonal treatment in not increasing the incidence of OSA.
LAM is structurally characterised by gradual replacement of lung parenchyma by thin wall cysts, which functionally leads to progressive obstruction, diffusion impairment and finally hyperinflation detected in lung function tests. Our set of patients had mild to moderate obstructive and diffusion disorder, without rest hypoxaemia, and nocturnal hypoxaemia was mainly detected during irregular ventilation presented in REM sleep. There are several mechanisms underlying nonapnoeic oxygen desaturation during sleep that may explain why patients with LAM and without rest hypoxaemia desaturate during sleep. They include impairments in: functional residual capacity, ventilatory responses to hypoxia and hypercapnia, respiratory mechanical effectiveness, arousal responses, respiratory muscle fatigue, chemical respiratory Among the functional variables evaluated, the RV/TLC ratio was the main variable related to nocturnal sleep desaturation. For instance, hyperinflation may be directly related to the impairment in the ventilation to perfusion ratio that occurs during recumbence in sleep in this set of patients. It may also intensify hypoventilation, because tonus is reduced and auxiliary respiratory muscles are inactivated. Although, we did not measure exhaled CO 2 , and therefore were not able to conclude that hypoventilation was the main phenomenon related to nocturnal sleep desaturation, the respiratory pattern (Figs. 1e4) observed during polysomnography suggests that hypoventilation might be an important concern in women with LAM during sleep. Since sleep had not been properly evaluated in LAM, and pulmonary function test results in LAM are very similar to those of COPD, we may infer that there may be some common physiologic mechanisms. COPD patients desaturate during sleep even in the absence of OSA, and one of the most important mechanisms is hypoventilation. Several studies have shown that recurrent transient hypoxaemia during sleep is frequent in patients with COPD. Nocturnal hypoxaemia is particularly marked in patients with "blue and bloated" clinical phenotype and frequently occurs during REM sleep. The measurement of minute ventilation with a pneumotachograph and oxygen saturation with pulse oximetry in a group of patients with severe Sleep desaturation and its relationship to lung function, exercise and quality of life in LAMCOPD demonstrated a nearly 20% lower SpO 2 during non-REM sleep and 40% lower oxygenation during REM sleep than during the awake state, primarily due to reduced tidal volume. 36, 37 Tidal volume small reductions, with little or no change in breathing frequency, are present from wakefulness to NREM sleep reducing alveolar ventilation. This phenomenon leads to a mild increase in arterial CO 2 tension of 2e8 mm Hg, despite a 10e30% fall in metabolic CO 2 production. Ventilation decline is particularly more pronounced during REM sleep, and severe oxygen desaturation especially occurs during bursts of rapid eye movements and might be intensified by the misbalance in ventilation-perfusion due to recumbence. Since the ventilatory response to hypoxia decreases by 33% during NREM sleep many subjects remain asleep with arterial saturation as low as 70% with no apparent NREMeREM differences. 36, 37 This mechanism may be responsible for the normal sleep efficiency found in our group of patients (88%), despite the fact that they did or did not desaturate during sleep.
In addition, chronic hypoxaemia has been associated with development of pulmonary hypertension, mainly through enhancement of prevascular resistance (potassium channel blockage and intracellular calcium influx) and misbalance in serotonin and endothelin actions. 39 Increased pulmonary arterial pressure has been detected during sleep in patients with COPD, and pulmonary hypertension and cor pulmonale are commonly seen in this set of patients. 40 Therefore, desaturation during sleep may represent an important predictor of severity and influence on patients with LAM quality of life, morbidity, and mortality as in COPD. 38e42 According to analysis of the questionnaires, we found that patients with nocturnal desaturation had more limitations in physical and emotional domains than the ones who did not. Impairments in quality of life related to health Our study has limitations that warrant discussion. First, it is possible that because of our sample size and mild functional impairments pulmonary hypertension was not observed and therefore no association with nocturnal hypoxaemia could be observed. Second, we do not have data about arterial blood gas either in rest or in exercise, which would have helped us evaluate respiratory functional status. Third, although we believe that hypoventilation was the main mechanism leading to nocturnal hypoxaemia, CO 2 levels were not measured during sleep, and so we are not able to confirm this hypothesis. However, the ventilatory pattern detected during REM versus NREM sleep may lead us to hypothesise that this could be an important mechanism associated with sleep desaturation.
In conclusion, in a survey of a LAM outpatient population, isolated nocturnal desaturation was very common and was present in more than half of patients. Hyperinflation was the main functional characteristic related to nocturnal sleep hypoxaemia. HRQOL impairment was more frequent among desaturators; physical and emotional roles were the most disturbed domains. Desaturation was more intense during sleep than during 6MWT, and patients with nocturnal desaturation did not have impaired sleep efficiency. Therefore, to stratify LAM severity and understand its progression, we believe that nocturnal oxygen desaturation during sleep must be investigated and ruled out in all patients with LAM.
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